US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

The downsizing of health federal agencies comes after Trump threatened to pull the US out of the World Health Organisation ...

The integration of AI in healthcare as a means by which to enhance diagnostic accuracy and treatment planning also appeared ...

From the impact of the new Trump Administration on research and development to advancements in brain health, PBM reform, and ...